Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
Dollar change
Percentage change
Index- P/E35.07 EPS (ttm)0.65 Insider Own2.76% Shs Outstand302.79M Perf Week-2.78%
Market Cap6.88B Forward P/E14.65 EPS next Y1.55 Insider Trans-0.18% Shs Float294.81M Perf Month0.40%
Income207.76M PEG1.85 EPS next Q0.23 Inst Own87.15% Short Float2.32% Perf Quarter0.00%
Sales1.83B P/S3.76 EPS this Y91.64% Inst Trans-1.96% Short Ratio3.04 Perf Half Y6.87%
Book/sh7.48 P/B3.04 EPS next Y24.39% ROA6.85% Short Interest6.83M Perf Year15.58%
Cash/sh3.28 P/C6.91 EPS next 5Y19.00% ROE8.74% 52W Range18.08 - 24.34 Perf YTD-5.38%
Dividend Est.- P/FCF23.50 EPS past 5Y-21.77% ROI8.47% 52W High-6.74% Beta0.58
Dividend TTM- Quick Ratio3.30 Sales past 5Y17.31% Gross Margin96.04% 52W Low25.55% ATR (14)0.52
Dividend Ex-Date- Current Ratio3.34 EPS Y/Y TTM15.07% Oper. Margin9.34% RSI (14)44.76 Volatility2.36% 2.06%
Employees1310 Debt/Eq0.10 Sales Y/Y TTM13.60% Profit Margin11.35% Recom1.73 Target Price26.73
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q392.82% Payout0.00% Rel Volume0.79 Prev Close22.81
Sales Surprise-0.14% EPS Surprise17.54% Sales Q/Q13.15% EarningsFeb 06 AMC Avg Volume2.25M Price22.70
SMA20-3.30% SMA501.86% SMA2004.75% Trades Volume1,771,051 Change-0.48%
Date Action Analyst Rating Change Price Target Change
Apr-11-24Downgrade Barclays Overweight → Equal Weight $25
Dec-19-23Initiated BTIG Research Buy $27
Dec-15-23Initiated Citigroup Buy $31
Sep-26-23Initiated H.C. Wainwright Buy $28
Aug-22-23Reiterated Oppenheimer Outperform $25 → $29
Aug-08-23Initiated SVB Securities Market Perform $18
Jul-11-23Resumed Morgan Stanley Equal-Weight $21
May-10-23Resumed Piper Sandler Overweight $28
Mar-09-23Initiated Wells Fargo Overweight $23
Jan-26-23Initiated Credit Suisse Outperform $29
Mar-28-24 08:13AM
Mar-23-24 05:06AM
Mar-17-24 08:50AM
Mar-08-24 09:38AM
11:31AM Loading…
Mar-07-24 11:31AM
Mar-06-24 04:45PM
Mar-04-24 07:06PM
Mar-02-24 05:06AM
Feb-27-24 04:05PM
Feb-26-24 07:42AM
Feb-23-24 01:11PM
Feb-19-24 08:00AM
08:30AM Loading…
Feb-14-24 08:30AM
Feb-13-24 08:00AM
Feb-12-24 09:35AM
Feb-10-24 05:06AM
Feb-09-24 09:35AM
Feb-08-24 06:50PM
Feb-07-24 07:01PM
Feb-06-24 08:45PM
05:01PM Loading…
Feb-01-24 04:05PM
Jan-30-24 10:00AM
Jan-29-24 09:40AM
Jan-25-24 08:00AM
Jan-23-24 04:05PM
Jan-22-24 05:00PM
Jan-21-24 01:16PM
Jan-19-24 11:21AM
Jan-18-24 04:05PM
Jan-17-24 11:29AM
Jan-11-24 09:40AM
Jan-08-24 04:40PM
Jan-07-24 04:00PM
Jan-02-24 04:05PM
Dec-19-23 10:16AM
Dec-12-23 08:54AM
Dec-07-23 04:05PM
Dec-05-23 01:51PM
Dec-04-23 07:26PM
Dec-01-23 11:32AM
Nov-29-23 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
Nov-08-23 05:24PM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
Nov-01-23 07:00PM
Oct-30-23 10:00AM
Oct-28-23 05:06AM
Oct-27-23 04:58AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
Oct-22-23 02:30AM
Oct-19-23 06:51PM
Oct-18-23 04:05PM
Oct-12-23 11:40AM
Oct-09-23 02:03AM
Oct-02-23 09:49AM
Sep-20-23 02:15PM
Sep-18-23 09:16AM
Sep-16-23 05:06AM
Sep-15-23 10:23AM
Sep-13-23 11:23AM
Sep-12-23 08:00AM
Sep-11-23 12:31PM
Sep-08-23 11:30AM
Sep-07-23 08:43AM
Sep-06-23 09:33AM
Sep-05-23 11:40AM
Sep-04-23 10:34AM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorMar 21 '24Option Exercise19.5723,491459,71954,908Mar 25 07:31 PM
Garber Alan MDirectorMar 21 '24Sale24.0119,205461,11235,703Mar 25 07:31 PM
Haley Patrick J.EVP, CommercialFeb 23 '24Sale21.4547,0201,008,579384,866Feb 27 06:58 PM
JOHNSON DAVID EDWARDDirectorFeb 21 '24Buy20.70190,0003,932,7341,100,730Feb 22 05:08 PM
Haley Patrick J.EVP, CommercialDec 14 '23Option Exercise16.2950,000814,500357,687Dec 14 07:56 PM
Haley Patrick J.EVP, CommercialDec 14 '23Sale23.3550,0001,167,500307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 13 '23Sale23.0125,000575,250533,345Dec 14 07:55 PM
Haley Patrick J.EVP, CommercialDec 12 '23Sale22.5014,149318,352307,687Dec 14 07:56 PM
Hessekiel JeffreyEVP, General Counsel & SecDec 04 '23Sale22.0625,000551,500558,345Dec 04 06:22 PM
Hessekiel JeffreyEVP, General Counsel & SecNov 30 '23Sale22.0125,000550,250583,345Dec 04 06:22 PM
JOHNSON DAVID EDWARDDirectorNov 27 '23Buy21.61120,4092,602,038910,730Nov 29 04:30 PM
JOHNSON DAVID EDWARDDirectorNov 27 '23Sale21.61120,4092,602,038790,321Nov 29 04:30 PM
Aftab DanaCSO/EVP Disc & Trans ResearchAug 30 '23Sale22.474,600103,362399,943Sep 01 08:15 PM
MORRISSEY MICHAELPresident and CEOAug 28 '23Option Exercise15.31360,0005,511,600945,496Aug 30 09:48 PM
Senner Christopher J.EVP and CFOAug 04 '23Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 04 '23Sale20.6860,0001,240,800571,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03 '23Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03 '23Sale20.5160,0001,230,600571,631Aug 07 09:20 PM
Haley Patrick J.EVP, CommercialAug 03 '23Sale20.6730,553631,531285,467Aug 07 08:24 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01 '23Option Exercise14.7455,710821,165627,686Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01 '23Sale19.6355,7101,093,587571,976Aug 03 08:02 PM